Synonyms TC-5619 PubChem CID 16727410 ChEMBL CHEMBL1258006 Molar mass 361.437 g/mol | CAS Number 639489-84-2 UNII UM3821998K Formula C22H23N3O2 | |
 | ||
Bradanicline (INN, code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.
In May 2011, AstraZeneca declined to exercise its right to license the compound. In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults. It was being studied for cognitive and memory enhancement.
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013. It was also discontinued for ADHD, and no longer seems to be being developed.